Sagimet Biosciences Inc (SGMT) - Long-Term Debt to Capital Coefficient

Sagimet Biosciences (SGMT) operations to create treatments for liver pathologies are completely independent of economic cycles and GDP. This chart of stock quotes illustrates the price action of the biotech startup developing molecular fatty acid synthesis inhibitors, with the metric standing at 0.01. Finally, it should be noted that the company complies with basic environmental waste disposal standards while maintaining minimal climate impact.

This ratio determines the proportion of long-term liabilities to equity, reflecting the degree of financial leverage and the company's dependence on external borrowing over a long-term horizon. By analyzing the current long-term debt-to-equity trend, an investor assesses the risk of excessive debt load, which for Sagimet Biosciences (SGMT) is mitigated by the absence of in-house production facilities and the use of an efficient contract manufacturing model.